Sensitivity to FasL/TRAIL and TRIL receptors expression in primary Ph1-positive leukemia cells
| Patient no. . | Sex . | Age . | Derived cell line . | Onset/Relapse . | Sample . | Type of BCR-ABL . | Viability after 24-h culture3-150 . | Expression of TRAIL receptors, RFI3-152 . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Control, % . | FasL, % . | TRAIL, % . | TRAIL + RIK2, % . | DR4 . | DR5 . | |||||||
| Ph1-ALL | ||||||||||||
| 1 | M | 7 | — | Onset | BM | p190 | 89 ± 2 | 91 ± 1 | 90 ± 3 | 90 ± 1 | 1.0 | 1.2 |
| 2 | M | 8 | KOPN30bi | Onset | PB | p190 | 75 ± 4 | 71 ± 6 | 77 ± 4 | 78 ± 2 | 1.0 | 1.1 |
| 3 | M | 11 | KOPN57bi | Onset | PB | p190 | 84 ± 1 | 77 ± 2 | 34 ± 53-151 | 72 ± 33-151,3-153 | ND | ND |
| 4 | M | 4 | YAMN91 | Onset | PB | p190 | 80 ± 4 | 76 ± 1 | 52 ± 33-151 | 80 ± 23-153 | 1.0 | 1.5 |
| 5 | F | 12 | — | Onset | BM | p190 | 85 ± 1 | 93 ± 2 | 90 ± 4 | 95 ± 2 | 1.0 | 1.1 |
| 6 | M | 16 | — | Relapse | PB | p210 | 85 ± 1 | 95 ± 3 | 90 ± 3 | 95 ± 2 | ND | ND |
| 7 | M | 9 | — | Relapse | BM | p190 | 89 ± 1 | 90 ± 1 | 62 ± 53-151 | 86 ± 23-153 | ND | ND |
| 8 | F | 3 | YAMN73 | Relapse | PB | p2033-155 | 87 ± 1 | 69 ± 23-151 | 46 ± 33-151 | 78 ± 33-151,3-153 | 1.2 | 1.6 |
| 9 | F | 6 | — | Relapse | PB | p190 | 92 ± 2 | 87 ± 3 | 46 ± 33-151 | 88 ± 13-153 | 1.5 | 2.0 |
| 10 | F | 15 | — | Relapse | BM | ND | 93 ± 3 | 83 ± 3 | 66 ± 33-151 | 77 ± 23-151,3-153 | ND | ND |
| CML-BC | ||||||||||||
| 11 | M | 3 | — | — | PB | p210 | 91 ± 4 | 91 ± 3 | 88 ± 4 | 92 ± 2 | ND | ND |
| 12 | F | 11 | — | — | PB | p210 | NA# | NA | NA | NA | 2.2 | 2.9 |
| Patient no. . | Sex . | Age . | Derived cell line . | Onset/Relapse . | Sample . | Type of BCR-ABL . | Viability after 24-h culture3-150 . | Expression of TRAIL receptors, RFI3-152 . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Control, % . | FasL, % . | TRAIL, % . | TRAIL + RIK2, % . | DR4 . | DR5 . | |||||||
| Ph1-ALL | ||||||||||||
| 1 | M | 7 | — | Onset | BM | p190 | 89 ± 2 | 91 ± 1 | 90 ± 3 | 90 ± 1 | 1.0 | 1.2 |
| 2 | M | 8 | KOPN30bi | Onset | PB | p190 | 75 ± 4 | 71 ± 6 | 77 ± 4 | 78 ± 2 | 1.0 | 1.1 |
| 3 | M | 11 | KOPN57bi | Onset | PB | p190 | 84 ± 1 | 77 ± 2 | 34 ± 53-151 | 72 ± 33-151,3-153 | ND | ND |
| 4 | M | 4 | YAMN91 | Onset | PB | p190 | 80 ± 4 | 76 ± 1 | 52 ± 33-151 | 80 ± 23-153 | 1.0 | 1.5 |
| 5 | F | 12 | — | Onset | BM | p190 | 85 ± 1 | 93 ± 2 | 90 ± 4 | 95 ± 2 | 1.0 | 1.1 |
| 6 | M | 16 | — | Relapse | PB | p210 | 85 ± 1 | 95 ± 3 | 90 ± 3 | 95 ± 2 | ND | ND |
| 7 | M | 9 | — | Relapse | BM | p190 | 89 ± 1 | 90 ± 1 | 62 ± 53-151 | 86 ± 23-153 | ND | ND |
| 8 | F | 3 | YAMN73 | Relapse | PB | p2033-155 | 87 ± 1 | 69 ± 23-151 | 46 ± 33-151 | 78 ± 33-151,3-153 | 1.2 | 1.6 |
| 9 | F | 6 | — | Relapse | PB | p190 | 92 ± 2 | 87 ± 3 | 46 ± 33-151 | 88 ± 13-153 | 1.5 | 2.0 |
| 10 | F | 15 | — | Relapse | BM | ND | 93 ± 3 | 83 ± 3 | 66 ± 33-151 | 77 ± 23-151,3-153 | ND | ND |
| CML-BC | ||||||||||||
| 11 | M | 3 | — | — | PB | p210 | 91 ± 4 | 91 ± 3 | 88 ± 4 | 92 ± 2 | ND | ND |
| 12 | F | 11 | — | — | PB | p210 | NA# | NA | NA | NA | 2.2 | 2.9 |
M indicates male; F, female; BM, bone marrow; PB, peripheral blood; ND, not determined; NA, not available; and —, not applicable.
Data are shown as mean ± SE.
Significant reduction in viability (P < .01,t test).
RFI was determined by the ratio of mean fluorescence intensity for specific staining to that for control staining.
Significant increase in viability (P < .01,t test) in comparison with TRAIL treatment alone.
p203 corresponds to the Abl exon 2-spliced BCR-ABL protein.
#Sensitivity could not be evaluated because of complete spontaneous cell death in control culture.